Common Side Effects of Opdualag
Opdualag (nivolumab and relatlimab-rmbw) causes side effects typical of immune checkpoint inhibitors, often due to immune system overactivation. Most patients experience fatigue (around 50-60%), musculoskeletal pain (40-50%), rash (30-40%), pruritus (itching, 25-35%), diarrhea (25-30%), nausea (20-30%), and decreased appetite (15-25%). These usually appear within weeks of starting treatment and can be managed with supportive care.[1][2]
Serious Side Effects and Immune-Related Risks
Severe reactions occur in 20-30% of patients and may require stopping treatment or using corticosteroids. Key risks include:
- Endocrine issues: Hypothyroidism (15-20%), hyperthyroidism (10-15%), adrenal insufficiency (5-10%).
- Gastrointestinal: Colitis (10-15%), severe diarrhea.
- Skin: Severe rash or Stevens-Johnson syndrome (rare, <1%).
- Pulmonary: Pneumonitis (5-10%), potentially life-threatening.
- Hepatic: Hepatitis (5-10%).
- Neurological: Myocarditis, encephalitis (1-5%), or Guillain-Barré syndrome (rare).
Infusion reactions happen in 5-10% during or shortly after administration. Monitor for these, as they can mimic disease progression.[1][2][3]
Side Effects by Severity and Frequency
| Severity | Examples | Frequency |
|----------|----------|-----------|
| Mild-Moderate | Fatigue, rash, diarrhea, arthralgia | 40-60% |
| Severe (Grade 3-4) | Colitis, pneumonitis, hepatitis | 15-25% |
| Fatal (rare) | Myocarditis, toxic epidermal necrolysis | <1% |
Data from clinical trials (RELATIVITY-047) in unresectable/metastatic melanoma show higher rates with Opdualag vs. nivolumab alone.[2]
How Side Effects Differ from Nivolumab Alone
Opdualag combines PD-1 inhibition (nivolumab) with LAG-3 blockade (relatlimab), increasing immune-related adverse events by 10-20% compared to nivolumab monotherapy. LAG-3 addition raises hypothyroidism and rash risks but offers better efficacy in melanoma.[2][3]
Long-Term and Delayed Side Effects
Some effects persist or emerge months later, like ongoing endocrinopathies (up to 20% permanent) or neuropathy. Regular monitoring for 6-12 months post-treatment is standard.[1]
Patient Management and Warnings
Report new symptoms immediately. Avoid in patients with active autoimmune disease. Pregnancy risk: Category D—can cause fetal harm. Not studied in pediatrics.[1][3]
[1]: Opdualag Prescribing Information (FDA)
[2]: RELATIVITY-047 Trial Data (NEJM)
[3]: Opdualag Safety Profile (BMS Summary)